Patient-derived tumor organoids (PDTOs) shows great potential as a preclinical model. However, the current methods for establishing PDTOs primarily focus on modulating local properties, such as sub-micrometer topographies. Nevertheless, they neglect to capture the global millimeter or intermediate mesoscale architecture that have been demonstrated to influence tumor response to therapeutic treatment and tumor progression. In this study, we present a rapid technique for generating collagen bundles with an average length of 90 ± 27 μm and a mean diameter of 5 ± 1.5 μm from tumor tissue debris that underwent mechanical agitation following enzymatic digestion. The collagen bundles were subsequently utilized for the fabrication of biomimetic hydrogels, incorporating microbial transglutaminase (mTG) crosslinked gelatin. These biomimetic hydrogels, referred to as MC-gel, were specifically designed for patient-derived tumor organoids. The lung cancer organoids cultured in MC-gel exhibited larger diameters and higher cell viability compared to those cultured in gels lacking the mesoscale collagen bundle; moreover, their irregular morphology more closely resembled that observed in vivo. The MC-gel-based lung cancer organoids effectively replicated the histology and mutational landscapes observed in the original donor patient’s tumor tissue. Additionally, these lung cancer organoids showed a remarkable similarity in their gene expression and drug response across different matrices. This recently developed model holds great potential for investigating the occurrence, progression, metastasis, and management of tumors, thereby offering opportunities for personalized medicine and customized treatment options.
19 December 2025 in European Journal of Surgical Oncology
Background: Although multiple studies have confirmed that adjusting the time-of-day (ToDA) of immunotherapy and timing interval (TI) of chemoimmunotherapy can improve long-term outcomes in patients with advanced non-small cell lung cancer (NSCLC), whether this model similarly improves survival among patients with operable NSCLC has not been reported. Patients and methods: This dual-center, retrospective study included adult patients who received neoadjuvant chemoimmunotherapy (neoCIT) for clinical stage T1-4N0-3M0 NSCLC between January 2019 and December 2024. The impact of the ToDA of neoadjuvant immunotherapy (neoIO) on the efficacy and safety were analyzed. In addition, the inverse probability of treatment weighting (IPTW)-weighted Cox regression model was used to compare disease-free survival (DFS) and overall survival (OS) between patients who received either ≥75% (≥75% group) or <75% (<75% group) of the neoIO administrations before 14:00 h. Results: A total of 168 consecutive patients with a median follow-up of 30.3 months were included, of whom 123 patients (73.2%) were in the ≥75% group. Neoadjuvant treatment-related adverse events (neoTRAEs) occurred in 47.6% of the patients, including 63 (51.2%) and 17 (37.8%) patients in the ≥75% and <75% groups, respectively ( P = 0.122). Pathologic complete response occurred in 31.7% of the patients in the ≥75% group and in 20.0% of those in the <75% group ( P = 0.177); major pathologic response occurred in 59.3% and 48.9%, respectively ( P = 0.300). According to the results of the IPTW-weighted univariate Cox analysis, patients in the <75% group had worse 3-year rates of DFS (77.1% vs. 77.9%; P = 0.065) and OS (68.3% vs. 89.1%; P = 0.033). These findings remained robust to multivariate Cox regression models (DFS: hazard ratio [HR]ffoo, 2.858; 95% confidence intervals [CIs]: 1.239-6.692; P = 0.014; and OS: HR, 7.625; 95% CIs: 1.112-52.272; P = 0.039). Additionally, a shorter mean TI of patients who received neoCIT infusions (<23.5 vs. ≥23.5 hours) emerged as an independent factor associated with better OS (HR, 0.143; 95% CIs, 0.024-0.875; P = 0.035). Conclusions: Although early infusions of most neoIO drugs did not affect safety or efficacy, it showed a potential trend toward improving long-term survival. The corresponding immune microenvironment and molecular mechanisms need further exploration to guide the design of future prospective clinical studies.
26 April 2026 in Therapeutic Advances in Medical Oncology
Background: Several clinical trials of neoadjuvant chemoimmunotherapy (neoCIT) for patients with locally advanced oesophageal carcinoma have been reported recently, with promising anti-tumour efficacy. However, systematic evaluation of the treatment patterns and clinical outcomes in a real-world cohort is lacking. Objectives: This study aimed to describe the real-world treatment patterns and short- and long-term outcomes of neoCIT in patients with resected oesophageal squamous cell carcinoma (ESCC). Design: A multicentre retrospective cohort study. Methods: Data from patients with resected ESCC who received neoCIT in routine clinical practice between January 2020 and December 2022 were retrospectively collected from three tertiary centres in China. Results: A total of 324 consecutive patients were enrolled, and the majority (82.4%) received two cycles of neoCIT. In total, 225 patients achieved a radiographic partial response (PR), resulting in an objective response rate of 69.4%. The rates of minimally invasive oesophagectomy and radical resection were 71.9% and 98.5%, respectively. Fifty-nine patients (18.2%) experienced postoperative complications, and the most common complication was anastomotic leakage (10.2%). The pathological complete response and major pathological response rates were 27.2% and 37.0%, respectively. As of August 31, 2024, the median follow-up was 24.8 months. The estimated 3-year rates of disease-free survival and overall survival were 62.3% and 71.5%, respectively. Multivariate analyses revealed that tumour grade ( p = 0.047), number of neoadjuvant therapy cycles ( p = 0.042), resection status ( p = 0.043), pathological N stage ( p < 0.001) and adjuvant treatment ( p < 0.001) were independent prognostic factors for disease-free survival. However, advanced pathological N stage was identified as the sole independent factor that correlated with worse overall survival ( p < 0.001). Conclusion: This real-world study validates the clinical efficacy and safety of neoCIT for resected oesophageal squamous cell carcinoma while demonstrating encouraging survival outcomes.